image
Healthcare - Medical - Devices - NASDAQ - US
$ 10.67
-2.03 %
$ 418 M
Market Cap
-2.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one OFIX stock under the worst case scenario is HIDDEN Compared to the current market price of 10.7 USD, Orthofix Medical Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one OFIX stock under the base case scenario is HIDDEN Compared to the current market price of 10.7 USD, Orthofix Medical Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one OFIX stock under the best case scenario is HIDDEN Compared to the current market price of 10.7 USD, Orthofix Medical Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OFIX

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
799 M REVENUE
7.08%
-84.6 M OPERATING INCOME
39.17%
-126 M NET INCOME
16.78%
25.8 M OPERATING CASH FLOW
156.37%
-27.6 M INVESTING CASH FLOW
16.75%
50.7 M FINANCING CASH FLOW
-22.37%
194 M REVENUE
-10.21%
-48.9 M OPERATING INCOME
-325.83%
-53.1 M NET INCOME
-82.16%
-18.4 M OPERATING CASH FLOW
-77.50%
-6.74 M INVESTING CASH FLOW
-493.48%
-651 K FINANCING CASH FLOW
-2.07%
Balance Sheet Orthofix Medical Inc.
image
Current Assets 433 M
Cash & Short-Term Investments 83.2 M
Receivables 135 M
Other Current Assets 215 M
Non-Current Assets 460 M
Long-Term Investments 0
PP&E 140 M
Other Non-Current Assets 320 M
9.32 %15.08 %24.11 %15.65 %35.85 %Total Assets$893.3m
Current Liabilities 169 M
Accounts Payable 48.8 M
Short-Term Debt 4.78 M
Other Current Liabilities 115 M
Non-Current Liabilities 222 M
Long-Term Debt 175 M
Other Non-Current Liabilities 46.7 M
12.51 %29.49 %44.81 %11.97 %Total Liabilities$390.2m
EFFICIENCY
Earnings Waterfall Orthofix Medical Inc.
image
Revenue 799 M
Cost Of Revenue 254 M
Gross Profit 546 M
Operating Expenses 631 M
Operating Income -84.6 M
Other Expenses 41.4 M
Net Income -126 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)799m(254m)546m(631m)(85m)(41m)(126m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.28% GROSS MARGIN
68.28%
-10.58% OPERATING MARGIN
-10.58%
-15.76% NET MARGIN
-15.76%
-25.04% ROE
-25.04%
-14.10% ROA
-14.10%
-11.80% ROIC
-11.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Orthofix Medical Inc.
image
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -126 M
Depreciation & Amortization 76 M
Capital Expenditures -34.9 M
Stock-Based Compensation 32.5 M
Change in Working Capital 0
Others 60.7 M
Free Cash Flow -9.09 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Orthofix Medical Inc.
image
Wall Street analysts predict an average 1-year price target for OFIX of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OFIX Lowest Price Target Wall Street Target
24 USD 124.93%
OFIX Average Price Target Wall Street Target
24 USD 124.93%
OFIX Highest Price Target Wall Street Target
24 USD 124.93%
Price
Max Price Target
Min Price Target
Average Price Target
24242222202018181616141412121010Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Orthofix Medical Inc.
image
Sold
0-3 MONTHS
58.3 K USD 2
3-6 MONTHS
145 K USD 3
6-9 MONTHS
427 K USD 3
9-12 MONTHS
0 USD 0
Bought
1.45 M USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 13, 2025 at 9:00 am Eastern Time. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.or. businesswire.com - 1 week ago
Orthofix to Report Second Quarter 2025 Financial Results LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing. businesswire.com - 1 week ago
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers. “I have b. businesswire.com - 1 month ago
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Caitlin Cronin - Canaccord Genuity Jeffrey Cohen - Ladenburg Operator Thank you for standing by. My name is Tina, and I will be your conference operator today. seekingalpha.com - 2 months ago
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates Orthofix (OFIX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago. zacks.com - 2 months ago
Orthofix Reports First Quarter 2025 Financial Results LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product. businesswire.com - 2 months ago
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT. businesswire.com - 4 months ago
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. globenewswire.com - 4 months ago
Orthofix Announces Appointment of Vickie Capps to Board of Directors LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously. businesswire.com - 4 months ago
Orthofix to Participate in the 37th Annual Roth Conference LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Posti. businesswire.com - 4 months ago
Orthofix (OFIX) Q4 Earnings Lag Estimates Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago. zacks.com - 4 months ago
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 202. businesswire.com - 4 months ago
8. Profile Summary

Orthofix Medical Inc. OFIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 418 M
Dividend Yield 0.00%
Description Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact 3451 Plano Parkway, Lewisville, TX, 75056 https://www.orthofix.com
IPO Date April 24, 1992
Employees 1616
Officers Mr. Massimo Calafiore President, Chief Executive Officer & Director Ms. Jill Mason Chief Compliance & Risk Officer Ms. Stephanie Walsh Chief Human Resources Officer Mr. Geoffrey C. Gillespie Chief Accounting Officer Ms. Julie D. Dewey Chief Investor Relations & Communications Officer Ms. Julie B. Andrews Chief Financial Officer Mr. J. Andres Cedron Chief Legal Officer & Corporate Secretary Mr. Lucas S. Vitale Chief People & Business Operations Officer Ms. Aviva McPherron President of Global Operations & Quality Mr. Max Reinhardt President of the Global Spine Business